Ming Hsieh

Ming Hsieh is the president and CEO of Fulgent Genetics and co-founder of Fulgent Therapeutics. He has been instrumental in the development of innovative cancer therapies, including FID-007, a novel chemotherapy that utilizes nanoparticles to enhance drug delivery directly to tumors. Recently, he shared promising preliminary results from phase 2 trials of FID-007 at a conference, highlighting its potential effectiveness in treating recurrent or metastatic head and neck squamous cell carcinoma.